David R. Epstein Sells 370 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 370 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $53.31, for a total transaction of $19,724.70. Following the sale, the director now directly owns 27,524 shares in the company, valued at $1,467,304.44. This trade represents a 1.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Tempus AI Stock Down 6.1 %

NASDAQ TEM opened at $64.99 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The company has a 50 day moving average of $44.36 and a 200-day moving average of $48.84. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49.

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of the company. First Horizon Advisors Inc. bought a new position in Tempus AI in the 3rd quarter valued at about $30,000. FNY Investment Advisers LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $67,000. IFP Advisors Inc acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $76,000. US Bancorp DE bought a new position in Tempus AI in the fourth quarter valued at approximately $80,000. Finally, Vestor Capital LLC acquired a new position in Tempus AI during the third quarter valued at approximately $153,000. Institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wolfe Research began coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. TD Cowen reaffirmed a “buy” rating and issued a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $56.00 target price on shares of Tempus AI in a report on Tuesday, January 14th. Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Finally, Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and an average target price of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.